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Background. Non-steroidal anti-inflammatory drugs are known
to promote sodium retention and to blunt the blood pressure
lowering effects of several classes of antihypertensive agents
including beta-blockers, diuretics and angiotensin converting en-
zyme (ACE) inhibitors. The purpose of the present study was to
investigate the acute and sustained effects of indomethacin on the
renal response to the angiotensin II receptor antagonist valsartan
and to the ACE inhibitor enalapril.
Methods. Twenty normotensive subjects maintained on fixed
sodium intake (100 mmol sodium/day) were randomized to re-
ceive for one week: valsartan 80 mg o.d., enalapril 20 mg o.d.,
valsartan 80 mg o.d. 1 indomethacin 50 mg bid and enalapril 20
mg o.d. 1 indomethacin 50 mg bid. This single-blind study was
designed as a parallel (valsartan vs. enalapril) and cross-over trial
(valsartan or enalapril vs. valsartan 1 indomethacin or enalapril
1 indomethacin). Renal hemodynamics and urinary electrolyte
excretion were measured for six hours after the first and seventh
administration of each treatment regimen.
Results. The results show that valsartan and enalapril have
comparable renal effects characterized by no change in glomeru-
lar filtration rate and significant increases in renal plasma flow and
sodium excretion. The valsartan- and enalapril-induced renal
vasodilation is not significantly blunted by indomethacin. How-
ever, indomethacin similarly abolishes the natriuresis induced by
the angiotensin II antagonist and the ACE inhibitor.
Conclusions. This observation suggests that although angioten-
sin receptor antagonists do not affect prostaglandin metabolism,
the administration of a non-steroidal anti-inflammatory drug
blunts the natriuretic response to angiotensin receptor blockade.
The renin-angiotensin system and renal prostaglandins
are two important factors contributing to the control of
renal hemodynamics and urinary electrolyte excretion [1].
Angiotensin II modulates renal perfusion and glomerular
filtration rate through its effects on renal arterioles and
glomerular mesangial cells [2]. Angiotensin II also has a
direct effect on proximal tubular sodium reabsorption and
an indirect influence on sodium handling by the distal
tubule via its ability to stimulate the release of aldosterone
[2, 3]. Lastly, angiotensin II exerts a negative feedback on
renin release. The renal prostaglandins tend to counterbal-
ance the vasoconstrictor and antinatriuretic effects of an-
giotensin II, promoting a renal vasodilation and sodium
excretion through their effects on renal arterioles and
medullary blood flow and their influence on tubular sodium
reabsorption [1, 4]. In addition, the release of renin from
juxtamedullary cells is modulated by the synthesis of pros-
taglandin I2 [1]. The renal homeostatic role of prostaglan-
dins becomes particularly important in conditions of salt
and/or water depletion that is, when vasoconstrictor sys-
tems are stimulated.
Clinically, the co-administration of non-steroidal anti-
inflammatory drugs (NSAIDs) and antihypertensive agents
often results in blunting of the effect of antihypertensive
therapy [5, 6]. The mechanism of this drug interaction
appears to involve the inhibition of vascular and renal
prostaglandin synthesis leading to vasoconstriction and
sodium retention [5]. The risk of interaction is greatest in
elderly and low-renin hypertension, and occurs most fre-
quently with the use of diuretics, beta-blockers and ACE-
inhibitors. No interaction has been reported with centrally-
acting alpha agonists and calcium channel blockers [6–8].
Because ACE inhibitors such as captopril have been found
to stimulate the production of prostaglandins in vitro as well
as in vivo, it has been proposed that some of the renal
effects of ACE inhibitors are in fact mediated by prosta-
glandins [9, 10]. These observations have supported the
hypothesis that ACE inhibitors act not only by inhibiting
angiotensin II formation, but also by preventing the degra-
dation of bradykinin that partly acts via vasodilatory pros-
taglandin release.
Recently, several nonpeptide, orally-active angiotensin II
receptor antagonists have been developed that specifically
block the angiotensin AT1 receptor subtype. Studies in
hypertensive patients have demonstrated that these antag-
onists are comparable to ACE inhibitors in their ability to
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lower blood pressure in hypertensive patients [11]. In
addition, angiotensin II receptor blockade and ACE inhi-
bition appear to have similar impacts on renal hemodynam-
ics, sodium excretion and urinary protein excretion [12–14].
In contrast to ACE inhibitors, these antagonists block the
renin-angiotensin system without interfering with the me-
tabolism of kinins and prostaglandins [15]. Thus, if prosta-
glandins contribute to the renal response to ACE inhibi-
tion, this should not be the case during angiotensin II
receptor blockade. Thus far, the interaction between
NSAIDs and angiotensin II receptor antagonists has never
been evaluated in humans.
The purpose of this study was to examine the effect of
indomethacin, an inhibitor of prostaglandin synthesis, on
the renal response to angiotensin II receptor blockade by
valsartan and to compare it to its interaction with the ACE
inhibitor enalapril. Our results demonstrate that indometh-
acin has no significant effect on the renal vasodilation
caused by angiotensin II receptor blockade and ACE
inhibition. However, indomethacin abolishes both the val-
sartan- and the enalapril-induced sodium excretion. This
suggests that the interaction between NSAIDs and ACE
inhibitors is not class-specific.
METHODS
Twenty healthy white male volunteers aged 20 to 35 years
(mean 24.9 years) weighing 74.8 kg (range 60 to 94 kg)
completed this study. Each volunteer had a medical history
taken and underwent a complete physical examination.
Their baseline systolic and diastolic blood pressures were
121.4 6 2.0 and 76.0 6 1.9 mm Hg, respectively (mean 6
SEM). Routine laboratory tests were done before and after
administration of the drug. The nature and the purpose of
the study had been explained, and written informed con-
sent had been obtained previously from each subject. The
protocol was approved by the Hospital Ethics Committee
(CHUV, Lausanne, Switzerland).
Study design
The study was designed as a parallel and crossover trial
with valsartan (80 mg) and valsartan (80 mg) 1 indometh-
acin (50 mg bid) in one arm and enalapril (20 mg) and
enalapril (20 mg) 1 indomethacin (50 mg bid) in the other
arm (Fig. 1). The two treatment phases each lasted seven
days and were separated by a one-week washout period.
Ten subjects were randomized to receive valsartan and
valsartan 1 indomethacin and 10 other subjects received
enalapril and enalapril 1 indomethacin. To reduce inter-
subject variability, the subjects were studied while they
were on a fixed sodium diet containing 100 mmol sodium
and 3500 calories per day. The diet began one week before
drug administration and was maintained throughout the
study, that is, for 28 days. The diet was provided, under the
supervision of a dietician, by the hospital restaurant where
the subjects ate all their meals. Diet compliance was
evaluated by repeated 24-hour urine collections.
On day 1 (after at least 1 week of diet), the volunteers
came to the hospital at 7 a.m. after an overnight fast to
undergo clearance studies. Upon arrival, they were made
comfortable on a bed. They remained supine, except for
voiding, and fasted throughout the study procedure. Two
intravenous catheters were inserted into antecubital veins,
one for the infusion of inulin and para-aminohippurate
(PAH) in a glucose/saline solution and a second one into
the contralateral forearm for blood drawing.
Between 7:00 and 8:00 a.m., the volunteers drank an oral
water load of 5 ml/kg. After a priming dose, the i.v. infusion
Fig. 1. Schematic representation of the study
design. Ovals denote the determination of renal
function.
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of inulin and PAH was started; the infusions were calcu-
lated to provide plasma concentrations of approximately
400 mg/ml and 20 mg/ml, respectively. The volunteers were
asked to empty their bladder every 60 minutes before drug
intake and every two hours after drug intake. After each
voiding, a fixed amount of water (100 ml/hr) was given
orally to sustain urine output. After a two-hour equilibra-
tion period, two baseline measurements were performed
until the volunteers were in steady-state. These two mea-
surements were averaged to determine the baseline value
(T0 in Tables 1 and 2). At the end of the baseline period
(T0), the volunteers were randomized to receive their drug
in single-blinded fashion.
Blood pressure, heart rate, urinary electrolyte excretion
and clearances of inulin and PAH to assess glomerular
filtration rate (GFR) and effective renal plasma flow
(ERPF) were measured at one hour intervals before drug
intake and at two hour intervals for six hours after drug
administration. Simultaneously, blood samples were drawn
for the measurement of electrolytes. Blood pressure was
obtained from the patients in a supine position and was
measured by the conventional auscultatory method. Blood
samples for the determination of plasma renin activity were
drawn after one hour in supine position in the morning of
day 1 and day 7 before drug intake.
On study days 2 to 7, the morning doses of valsartan,
enalapril and indomethacin were administered between 8
and 9 a.m. The evening dose of indomethacin was admin-
istered bewteen 6 and 8 p.m. Blood pressure (BP) and
heart rate were measured with the patient in a supine
position before the drug was given. Body weight and
24-hour urinary sodium, potassium and creatinine excre-
tion were measured every day during drug administration.
On day 7, renal clearances were repeated as on day 1.
Table 1. Acute (day 1) hemodynamic and tubular effects of indomethacin during angiotensin II receptor blockade and angiotensin converting
enzyme (ACE) inhibition
Parameter
Valsartan Valsartan 1 Indomethacin Enalapril Enalapril 1 indomethacin
T0 T4 T0 T4 T0 T4 T0 T4
SBP mm Hg 109 6 2.6 112 6 2.6 108 6 2.3 111 6 1.9 107 6 2.2 104 6 2.2 109 6 2.3 106 6 3.2
DBP mm Hg 73 6 1.5 56 6 2.5b 70 6 2.2 63 6 2.9a 68 6 2.6 59 6 3.1b 69 6 1.5 62 6 2.7b
HR bpm 56 6 2.7 67 6 4.0 57 6 1.8 63 6 2.3 60 6 2.7 72 6 4.7 63 6 3.1 68 6 3.9
GFR ml/min/1.73 m2 121 6 6.2 117 6 7.6 121 6 7.8 119 6 9.4 124 6 8.0 120 6 8.1 128 6 6.1 126 6 6.2
ERPF ml/min/1.73 m2 540 6 42 598 6 34 558 6 52 581 6 65 580 6 38 637 6 34 622 6 33 639 6 47
FF % 23.1 6 1.2 19.9 6 1.4 23.4 6 2.3 21.9 6 2.1 21.8 6 1.1 18.9 6 0.8a 20.9 6 0.1 20.4 6 1.3
UNaV mmol/min 107 6 16 176 6 23
a 101 6 18 103 6 12.2 143 6 16 181 6 18a 154 6 22.9 111 6 16.2
UKV mmol/min 80.2 6 8.0 55.6 6 5.8
b 77.7 6 9.3 59.3 6 6.8a 71.2 6 7.8 36.4 6 4.8b 73.3 6 6.1 43.7 6 5.9b
FENa % 0.69 6 0.10 1.28 6 0.13
a 0.68 6 0.10 0.68 6 0.06 0.99 6 0.14 1.28 6 0.14a 0.99 6 0.13 0.73 6 0.11
FEK % 17.8 6 1.8 14.5 6 1.4 18.4 6 2.4 14.1 6 1.5 16.8 6 2.0 9.0 6 0.9 16.5 6 1.3 9.8 6 1.1
FELi % 25.7 6 2.0 21.4 6 1.6 23.6 6 1.8 17.6 6 1.2
b 26.9 6 2.5 22.8 6 1.6 26.3 6 3.8 20.2 6 2.3
Abbreviations are: SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; GFR, glomerular filtration rate; ERPF, effective renal
plasma flow; and FF, filtration fraction. UxV, urinary excretion of x in micromoles per minute; FEx, fractional excretion of x or clearance of x divided
by glomerular filtration rate. T0 and T4 indicate baseline value and value 4 hours after drug intake, respectively.
a P , .05
b P , .01 vs. T0
Table 2. Sustained (day 7) hemodynamic and tubular effects of indomethacin during angiotensin II receptor blockade and ACE inhibition
Parameter
Valsartan Valsartan 1 Indomethacin Enalapril Enalapril 1 Indomethacin
T0 T4 T0 T4 T0 T4 T0 T4
SBP mm Hg 105 6 1.6 110 6 2.3 103 6 2.7 112 6 3.3 104 6 2.3 104 6 1.8 105 6 0.9 107 6 2.7
DBP mm Hg 69 6 1.5 62 6 2.3 68 6 2.1 63 6 3.0 66.1 6 2.7 54 6 3.0 66 6 1.9 57 6 2.3
HR bpm 56 6 1.7 68 6 3.0 55 6 1.3 65 6 3.3 60 6 3.3 71 6 3.1 61 6 2.9 68 6 3.8
GFR ml/min/1.73 m2 119 6 6.9 119 6 6.9 118 6 7.9 117 6 12.0 114 6 8.6 115 6 6.9 123 6 7.0 112 6 7.3
ERPF ml/min/1.73 m2 515 6 38 644 6 46b 561 6 50 589 6 42 562 6 40 658 6 41 597 6 36 664 6 41
FF % 24.6 6 2.1 19.3 6 1.6 22.0 6 1.7 20.1 6 1.7 20.5 6 1.1 17.8 6 1.2 20.9 6 1.2 17.1 6 1.0
UNaV mmol/min 64 6 7 134 6 14
b 98 6 15 80 6 7 102 6 19 155 6 22a 136 6 15.5 106 6 7.3
UKV mmol/min 65 6 7.2 60 6 9.1 76 6 9.3 62 6 7.4 91 6 10.0 60 6 5.9
b 94 6 14.8 48 6 5.4b
FENa, % 0.45 6 0.06 0.92 6 0.11
b 0.62 6 0.09 0.56 6 0.05 0.76 6 0.15 1.11 6 0.16a 0.93 6 0.11 0.79 6 0.07
FEK, % 15.7 6 2.1 14.7 6 2.1 16.5 6 1.8 15.2 6 1.7 22.0 6 2.3 14.5 6 1.1 20.8 6 3.1 11.6 6 0.9
FELi, % 26.8 6 2.6 24.6 6 2.8 23.0 6 1.8 20.9 6 2.1 29.8 6 2.5 26.3 6 2.1 24.3 6 2.4 19.7 6 2.4
Abbreviations are: SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; GFR, glomerular filtration rate; ERPF, effective renal
plasma flow; and FF, filtration fraction. UxV, urinary excretion of x in micromoles per minute; FEx, fractional excretion of x or clearance of x divided
by glomerular filtration rate. T0 and T4 indicate baseline value and value 4 hours after drug intake, respectively.
a P , .05
b P , .01 vs. T0
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Drugs and chemicals
Valsartan, enalapril and indomethacin were provided by
Novartis, Basel, Switzerland. Inulin was purchased from
Laevosan Gesellschaft (Linz, Austria) and PAH (Nephro-
test, sodium salt of para-aminohippuric acid) was from
Biologische Arbeitsgemeinschaft GmBH (Lich, Essen,
Germany). The gluco-saline solution contained 51 mmoles
Na/liter. During the clearance days, 60 to 65 mmoles of Na
were infused.
Analytic methods
Plasma and urinary inulin concentrations were measured
by a microadaptation of a diphenylamine procedure on a
Technicon Autoanalyser [16]. PAH concentrations were
determined by spectrophotometry [17]. Plasma and urinary
sodium, potasssium and chloride were analyzed with selec-
tive electrodes (Hel-ISE; Beckman). Endogenous trace
lithium was measured by electrothermal absorption spec-
trophotometry as described by Magnin et al [18]. Intraday
and interday coefficient of variations for plasma lithium
were 7 and 10%, respectively. For the determination of
plasma renin activity (PRA), generated angiotensin I was
trapped and quantitated by high affinity antibodies [19].
Calculation of renal parameters
Clearances (C), filtration fraction and fractional excre-
tion were calculated by the traditional formula [14]. Frac-
tional excretion (FEx) was calculated as the clearance of x
divided by the glomerular filtration rate. The coefficients of
variation for two determinations of inulin and PAH clear-
ances and FELi in the same conditions but at two week
intervals were 5%, 13% and 20.3%, respectively (N 5 20).
Statistical analysis
All results are expressed as mean 6 1 SEM. Differences
were assessed by an analysis of covariance or an analysis of
covariance followed by paired Student t-test when appro-
priate with a value of P , 0.05 as the level of significance.
We looked for significant changes within and between the
groups.
RESULTS
After one week of the diet, the two groups of ten
volunteers were comparable in terms of age, body wt,
systolic and diastolic BPs, heart rate and renal hemodynam-
ics. In addition, the value of the last 24-hour urinary sodium
excretion before the first drug administration were: 95 6 11
mmol/day in the valsartan group, 91 6 14 mmol/day in the
valsartan 1 indomethacin group, and 80 6 11 mmol/day in
the enalapril and 88 6 14 mmol/day in the enalapril 1
indomethacin group (P 5 NS between groups). There were
no significant hemodynamic, biochemical or hormonal dif-
ferences between the four treatment groups at baseline.
The administration of valsartan, enalapril and indometha-
cin was well tolerated by all subjects, and no significant
clinical or laboratory side effect was observed. Two subjects
withdrew consent and were replaced.
Effects of indomethacin on the acute response to
valsartan and enalapril
The effects of indomethacin on the acute hemodynamic
and tubular effects of valsartan and enalapril are presented
in Table 1. In these moderately salt-depleted subjects, both
valsartan and enalapril induced a significant, transient
decrease in diastolic BP with no change in systolic BP. The
maximal change in pressure was observed four hours after
drug intake with both agents. The decreases in diastolic BP
were slightly less when valsartan and enalapril were co-
administred with indomethacin, but the differences were
not statistically significant.
Valsartan and enalapril had no significant effect on GFR
nor did the co-administration of indomethacin, although a
slight but nonsignificant decrease in GFR was noted two
hours after the administration of indomethacin (Fig. 2A).
In contrast, a significant increase in ERPF was observed
with valsartan and enalapril. The maximal effect on ERPF
was observed six hours after drug intake (P 5 0.005 at 6 hr
vs. baseline in the valsartan group and P 5 0.03 at 6 hr in
the enalapril group). Indomethacin did not affect the
valsartan- and the enalapril-induced renal vasodilation
(Fig. 2B). A slight decrease in filtration fraction was found
both with valsartan and enalapril but only the changes
induced by enalapril reached statistical significance (Table
1). No significant change in filtration fraction was found in
the indomethacin-treated groups.
As shown in Figure 2C, similar significant increases in
urinary sodium excretion were found both with valsartan
and enalapril. Indomethacin equally abolished the natri-
uretic response to angiotensin II receptor blockade and
ACE inhibition. Indeed, at two and four hours, the natri-
uretic response to valsartan was significantly blunted by
indomethacin (P 5 0.004 at 2 hr and P 5 0.025 at 4 hr for
valsartan vs. valsartan 1 indomethacin). A similar effect
was found with enalapril (P 5 0.06 at 2 hr and P 5 0.011 at
4 hr, enalapril vs. enalapril 1 indomethacin). The cumula-
tive six-hour sodium excretion was significantly reduced by
the administration of indomethacin (P 5 0.013, valsartan
vs. valsartan 1 indomethacin, and P 5 0.009, enalapril vs.
enalapril 1 indomethacin). Urinary potassium excretion
decreased significantly in all groups but no significant
difference was found between the groups. The variations in
FELi were not significant in the valsartan and enalapril
groups. However, in the valsartan 1 indomethacin group,
significant decreases in FELi were observed two and four
hours after the administration of indomethacin (P 5 0.01).
The changes in FELi observed in the enalapril 1 indometh-
acin group was of equal magnitude but did not reach
statistical significance.
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Effects of indomethacin on the sustained renal response
to valsartan and enalapril
After one week of valsartan and enalapril alone or
combined with indomethacin, no significant change in
blood pressure was found in the four treatment groups.
From day 1 to day 7, supine plasma renin activity increased
from 1.23 6 0.2 to 3.0 6 0.5 ng Ang I/ml/hr with valsartan
(P 5 0.001), from 1.02 6 0.15 to 2.0 6 0.45 with valsartan
1 indomethacin (P 5 ns), from 0.97 6 0.15 to 3.2 6 0.6
with enalapril (P 5 0.011), and from 0.85 6 0.08 to 2.6 6
0.7 with enalapril 1 indomethacin (P 5 NS). Cumulative
one week sodium excretion was slightly greater in the
valsartan than in valsartan 1 indomethacin group (607 6
25 vs. 581 6 30 mmol/week, P 5 0.07) and in the enalapril
group as compared to the enalapril 1 indomethacin group
(704 6 39 vs. 635 6 41 mmol/week, P 5 0.043). After one
week, sodium balance was not different in the valsartan 1
indomethacin and the enalapril 1 indomethacin groups.
No significant change in cumulative potassium excretion
was observed between the groups and cumulative creati-
nine excretion was comparable in all groups. Body weight
decreased with valsartan and enalapril and remained
slightly higher when indomethacin was added to either
blocker of the renin-angiotensin system.
The effects of indomethacin on the renal response to
angiotensin II receptor blockade and ACE inhibition on
day 7 are shown in Table 2. No significant change in blood
pressure, heart rate and GFR was observed after repeated
Fig. 2. Acute changes in glomerular filtration
rate (GFR; A), effective renal plasma flow
(ERPF; B) and urinary sodium excretion
(UNaV; C) induced by valsartan (l), valsartan
1 indomethacin (E), enalapril (f) and
enalapril 1 indomethacin (M) on day 1. Values
are means 6 SEM; *P , 0.05, **P , 0.01 versus
time 0.
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administration of valsartan or enalapril alone or combined
with indomethacin. As shown on Figure 3B, an equal
increase in ERPF was again observed upon administration
of valsartan and enalapril with a maximal effect at six hours
(P 5 0.005 baseline vs. 6 hr with valsartan and P 5 0.0001
with enalapril). The coadministration of indomethacin ap-
peared to blunt the renal vasodilatory effect of valsartan
(P 5 NS, baseline vs. 6 hr in the valsartan 1 indomethacin
group) but there was no significant difference between the
valsartan and the valsartan 1 indomethacin groups. Indo-
methacin had no effect on the response to enalapril (P 5
0.02 baseline vs. 6 hr in the enalapril 1 indomethacin). As
observed on day 1, both the administration of valsartan and
enalapril increased sodium excretion (UNaV and FENa) and
this natriuretic response was again abolished by indometh-
acin (Fig. 3C). Potassium excretion decreased significantly
in all four treatment groups. On day 7, no significant
change in FELi was found within and between the groups.
DISCUSSION
This study demonstrates that the angiotensin II receptor
antagonist valsartan and the ACE inhibitor enalapril have
comparable acute and sustained renal hemodynamic and
tubular effects, leading to significant increases in effective
renal plasma plasma flow and urinary sodium excretion
without affecting glomerular filtration rate. In addition, the
Fig. 3. Changes in GFR (A), ERPF (B) and
urinary sodium excretion (UNaV; C) induced by
valsartan (v), valsartan 1 indomethacin (E),
enalapril (f) and enalapril 1 indomethacin
(M) on day 7. Values are means 6 SEM; *P ,
0.05, **P , 0.01 versus time 0.
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present data show for the first time, to our knowledge, in
humans that the administration of a nonsteroidal anti-
inflammatory agent abolishes the natriuretic, but not the
renal hemodynamic response to angiotensin II receptor
blockade. Since indomethacin similarly inhibits the natri-
uresis induced by valsartan and by enalapril, our results
suggest that the antagonistic effect of NSAIDs is not
class-specific.
Hemodynamic effects
During salt-depletion, blood pressure becomes renin-
dependent and a fall in blood pressure can be expected
when the renin-angiotensin system is blocked [20, 21]. In
our moderately salt-restricted normotensive subjects, val-
sartan and enalapril indeed lowered diastolic blood pres-
sure after the first dose and after one week of administra-
tion, blood pressure was still slightly but not significantly
reduced. The rather modest degree of salt restriction and
the difficulties to maintain a fixed sodium intake for almost
two weeks certainly account for the absence of a persistent
reduction in blood pressure during repeated administra-
tion. Although NSAIDs are known to produce mild eleva-
tions of blood pressure, particularly in hypertensive patients,
the co-administration of indomethacin with valsartan and
enalapril had no significant influence on blood pressure.
This suggests that NSAIDs have only a minor impact on
blood pressure in normotensive subjects who are on a
relatively low sodium intake regimen. This hypothesis is
supported by previous studies showing that ibuprofen
and/or indomethacin have no effect on blood pressure in
furosemide-treated normotensives [22] or in captopril-
treated subjects [23]. Moreover, a recent meta-analysis has
demonstrated that significant effects of NSAIDs on blood
pressure are observed almost uniquely in hypertensive
patients [24].
It is now well demonstrated that blockade of the renin-
angiotensin system with ACE inhibitors, renin inhibitors
and angiotensin II receptor antagonists enhances renal
blood flow without affecting GFR [12–14, 25–28]. In agree-
ment with these observations, we have found that both
valsartan and enalapril increase effective renal plasma flow,
whereas neither drug has an influence on GFR. Together
with the renin-angiotensin system, prostaglandins appear to
play a crucial role in maintaining an adequate renal perfu-
sion during salt-depletion [1, 29]. Thus, NSAIDs have been
shown to decrease renal blood flow and sometimes GFR in
salt-depleted normotensive subjects [29]. However, this
finding remains somewhat controversial. Indeed, many
investigators have reported little if any effect of indometh-
acin on renal hemodynamics in salt-depleted [30, 31] and
salt-repleted volunteers [32]. Whether prostaglandin syn-
thase inhibitors modulate the renal hemodynamic effects of
drugs inhibiting the renin-angiotensin system is also a
matter of debate. In normotensive subjects, ibuprofen has
been reported to blunt the captopril-induced increases in
GFR and ERPF [23], but in hypertensive patients indo-
methacin had no effect on renal plasma flow and GFR
when combined with trandolapril [33]. In our experience,
indomethacin had no influence on the changes in renal
hemodynamics induced by valsartan and enalapril. During
repeated administration, the valsartan-induced renal vaso-
dilation was slightly blunted by indomethacin, but the
difference did not reach a relevant level of statistical
significance.
Effects on urinary sodium excretion
Several studies in normotensive subjects have shown that
ACE inhibitors or angiotensin II receptor antagonists
increase urinary sodium excretion [25–28]. The results of
the present study largely confirm this general observation,
as both valsartan and enalapril equally increased urinary
sodium excretion within the first six hours after drug intake.
During repeated administration, a transient natriuretic
response could still be demonstrated, mainly with valsartan.
This observation is in accordance with our previous finding
in normal subjects receiving irbesartan for one week [26].
Whether NSAIDs interfere with the natriuresis induced by
angiotensin II receptor antagonists has, to our knowledge,
not been studied in humans to date. Our results clearly
indicate that indomethacin abolishes the natriuretic effect
of valsartan leading to a significant reduction of the valsar-
tan-induced six hour cumulative sodium excretion on day 1.
After one week of indomethacin, the cumulative sodium
excretion was still lower in the valsartan 1 indomethacin
group than in the valsartan group, but the difference was
less pronounced due the indidual variability. When com-
bined with enalapril, the effect of indomethacin was com-
parable on the first day. During repeated administration,
however, the effect on cumulative sodium excretion was
slightly more pronounced. Yet, sodium balance was not
different in the valsartan 1 indomethacin and in the
enalapril 1 indomethacin groups, suggesting that indo-
methacin blunts the natriuresis induced by the angiotensin
II receptor antagonist and the ACE inihibitor in a compa-
rable way.
Our finding, that indomethacin attenuates the natriuretic
effect of valsartan and enalapril similarly, provides some
interesting new insights on the role of prostaglandins as
potential mediators of the renal tubular effects of ACE
inhibitors and angiotensin II receptor antagonists. Indeed,
it has been postulated that ACE inhibitors may act by
mechanisms other than inhibition of angiotensin II gener-
ation. ACE inhibitors are known to inhibit the enzyme that
metabolizes bradykinin, which acts at least partly via the
release of vasodilatory prostaglandins. In addition, ACE
inhibitors may stimulate the production of prostaglandins,
an effect that can be blocked by indomethacin [9, 10]. It has
therefore been suggested that the effects of ACE inhibitors
on renal tubular function is mediated in part by prostaglan-
dins. In contrast to ACE inhibitors, angiotensin II receptor
Fricker et al: Indomethacin and the renal effect of valsartan 2095
antagonists have no influence on prostaglandins [15]. If
prostaglandins mediate some of the effects of ACE inhib-
itors, one could expect that urinary electrolyte excretion
differs during angiotensin II receptor blockade and ACE
inhibition. Our results do not support this hypothesis, since
comparable effects on sodium and potassium excretion
were observed with valsartan and enalapril. Several recent
studies have shown that ACE inhibitors and angiotensin II
receptor antagonists have similar effects on blood pressure,
renal hemodynamics, urinary protein and sodium excretion
in hypertensive patients and normotensive subjects [12–14,
25, 26]. Thus, the interaction of the NSAID with the
blockers of the renin-angiotensin system, valsartan and
enalapril, more likely results from the fact that these drug
classes have opposing effects on tubular sodium handling
that are mutually attenuated by the addition of the other
compound, as suggested earlier with ibuprofen and capto-
pril [23]. Therefore, the interaction of NSAIDs with ACE
inhibitors is probably not class-specific for the ACE inhib-
itors.
The ACE inhibitor-induced natriuresis appears to result
from a decrease sodium reabsorption in the proximal
segment of the nephron and via aldosterone reduction in
distal segments [27, 28]. Similar observations have been
reported with angiotensin II receptor antagonists although
a direct effect on sodium handling by the proximal tubule
has not always been demonstrated [25, 26]. In accordance
with our previous observations using other angiotensin II
antagonists, no clear effect of valsartan and enalapril on
proximal sodium reabsorption was observed with valsartan
as no significant change in lithium excretion was found.
This suggests a prominent effect of these agents on distal
sodium reabsorption in our experimental conditions [34].
The slight decrease in FELi observed four hours after the
administration of valsartan and enalapril reflects the indi-
vidual variability in lithium excretion. When both blockers
of the renin-angiotensin system were combined with indo-
methacin, however, more pronounced decreases in FELi
were found. This would indicate that indomethacin in-
creases sodium reabsorption in the proximal segments of
the nephron. This finding is in agreement with early
observations suggesting that indomethacin promotes so-
dium reabsorption in the proximal tubule [35] and/or in the
medullary thick ascending limb [36–38]. Whether a de-
crease in filtered load of sodium contributes to the antina-
triuretis cannot be ascertained from our data, since only
moderate and nonsignificant decreases in GFR were ob-
served in our subjects.
Taken together, this study demonstrates that although
angiotensin receptor antagonists do not affect prostaglan-
din metabolism, indomethacin abolishes the natriuretic
response to valsartan without affecting its renal hemody-
namic effects. The mechanism of the indomethacin-in-
duced change appears to be nonspecific as the NSAID
similarly blunts the natriuresis of the ACE inhibitor enala-
pril. Clinically, this pharmacodynamic interaction may be
very important in patients with hypertension or congestive
heart failure, as it may counteract the antihypertensive
efficacy of these agents. Our observation in normotensive
subjects may also be relevant for normotensive patients
receiving ACE inhibitors or angiotensin II receptor antag-
onists to prevent the progression of renal diseases.
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